fih study of arv-110 in metastatic castrate-resistant prostate cancer
Published 4 years ago • 220 plays • Length 1:33Download video MP4
Download video MP3
Similar videos
-
5:42
atezolizumab with radium-223 in metastatic castrate-resistant prostate cancer
-
4:46
quality of life and new therapeutic options for metastatic castration-resistant prostate cancer
-
2:10
current standards for first-line metastatic hormone-sensitive prostate cancer
-
2:16
testing the validity of a prognostic model for castration-resistant prostate cancer
-
1:26
current standards and future prospects for the treatment of hormone refractory prostate cancer
-
3:33
prophecy trial: ar-v7 ctcs as a biomarker in mcrpc
-
29:02
ar-v7 in castration resistant prostate cancer
-
27:12
myth busted: current studies of prostate cancer hormone resistance (boris alekseev)
-
1:52:45
aua guidelines on advanced/metastatic/castration resistant prostate cancer webcast (2021)
-
9:23
hormone-sensitive metastatic prostate cancer
-
20:51
novel therapies for castration-resistant prostate cancer
-
2:45
arrow: psma-targeted radioligand therapy plus enzalutamide in mcrpc
-
4:57
part 10 - management of castration resistant prostate cancer - role of radiation - dr. harsha
-
14:30
castration resistant prostate cancer aua guidelines
-
4:55
18f-fluciclovine pet in mcrpc treated with abiraterone acetate
-
7:46
prostate cancer: validation of ar-v7 testing
-
3:22
detection of ar-v7 in prostate cancer
-
6:30
ar-v7 as a predictive marker in prostate cancer
-
5:37
ar-v7 testing in mcrpc